文献速递胃肠外科围术期管理与 ERAS

抗凝治疗对微创胃肠大手术结局的影响

The effect of anticoagulation therapy on the surgical outcomes of minimally invasive major gastrointestinal surgery.
PubMed 文献 · Surg Endosc · 2024-12-16

本研究纳入2014至2023年接受择期微创胃肠大手术的1290例患者,分为非抗凝组(1076例)、DOAC组(144例)和华法林组(70例)。术后出血发生率分别为1.0%、6.9%和11.4%(P<0.001),DOAC和围术期肝素化是术后大出血的独立危险因素,提示抗凝患者需警惕迟发性出血。

要点

  • 抗凝患者行微创胃肠大手术总体安全,但术后出血风险显著高于非抗凝者。
  • DOAC组术后出血多发生于术后第5天及以后,需警惕迟发性出血。
  • DOAC和围术期肝素化是术后大出血的独立危险因素。

核心结论

  • 抗凝患者可安全接受微创胃肠大手术,但需警惕迟发性消化道出血,尤其是DOAC患者。
  • DOAC或围术期肝素化患者仍属术后出血高危人群,需谨慎管理。

研究设计与样本

  • 回顾性队列研究,纳入2014至2023年连续1290例择期微创(腹腔镜和机器人)胃肠大手术(食管胃及结直肠恶性肿瘤切除)患者。
  • 按抗凝状态分为非抗凝组(n=1076)、DOAC组(n=144)和华法林组(n=70),比较结局并用logistic多因素分析评估术后出血危险因素。

主要发现

  • 全队列血栓栓塞并发症总发生率为0.5%,手术死亡率为零。
  • 非抗凝组、DOAC组和华法林组术后出血发生率分别为1.0%、6.9%和11.4%(P<0.001)。
  • 8例DOAC组术后消化道出血患者中,75%的病例发生于术后第5天或更晚。
  • 多因素分析显示DOAC(OR=5.420,P<0.001)和围术期肝素化(OR=3.770,P=0.048)是术后大出血的显著危险因素。

临床怎么用

  • 对接受DOAC或围术期肝素化的患者,术后应加强出血监测,尤其关注术后第5天及以后的迟发性消化道出血。
  • 抗凝患者行微创胃肠大手术前需个体化评估出血与血栓风险,优化围术期抗凝管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The surgical outcomes of minimally invasive surgery (MIS) for gastrointestinal (GI) cancers in patients receiving anticoagulation therapy (ACT) are unknown. We investigated the effect of ACT on the surgical outcomes of minimally invasive major GI surgery, with a particular focus on postoperative bleeding and thromboembolic complications. METHODS: A total of consecutive 1290 patients undergoing elective minimally invasive (laparoscopic and robotic) major GI surgery (esophagogastric and colorectal resection for malignancy) between 2014 and 2023 were enrolled. The patients were divided into three groups: patients without receiving anticoagulation therapy (non-ACT, n = 1076), patients receiving direct oral anticoagulants (DOAC, n = 144), and patients receiving warfarin (WF, n = 70). Outcome variables were compared between the groups and the risk factors of postoperative bleeding complications were assessed using logistic multivariate analysis. RESULTS: The overall rate of thromboembolic complication was 0.5%, and the operative mortality was zero in the whole cohort. The incidences of postoperative bleeding in the non-ACT, DOAC, and WF groups were 1.0%, 6.9% and 11.4%, respectively (P < 0.001). Among 8 DOAC-received patients with postoperative GI bleeding, 75% of cases occurred on postoperative day 5 or later. Multivariate analysis showed DOAC (odds ratio = 5.420, P < 0.001) and perioperative heparinization (odds ratio = 3.770, P = 0.048) were significant risk factors for major postoperative bleeding. CONCLUSIONS: Although minimally invasive major GI surgery can be safely performed in patients receiving ACT, attention should be paid for the occurrence of delayed GI bleeding especially in the DOAC-received patients. Patients treated with DOAC or perioperative heparinization still represent a challenging group in the present cohort, and need to be carefully managed.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Harada K, Uemoto Y, Nagata K, et al. The effect of anticoagulation therapy on the surgical outcomes of minimally invasive major gastrointestinal surgery. Surg Endosc. 2024. PMID: 39681683. doi:10.1007/s00464-024-11465-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。